The response rate for patients with the FCGR@A R/R genotype was significantly increased when cetuximab was added to Nordic FLOX ( @ % versus @ % , interaction P = @ ) , but was not significantly different compared to the response rate of patients with the FCGR@A H/H or H/R genotypes given the same treatment .